Go Pro

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Accelerate Diagnostics logo

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

Key Stats

Today's Range
$0.03
$0.03
50-Day Range
$0.03
$1.18
52-Week Range
$0.03
$0.59
Volume
N/A
Average Volume
6.48 million shs
Market Capitalization
$857.14 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AXDX Stock News Headlines

A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.' Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.tc pixel
Accelerate Diagnostics Delays Q2 2025 Report
See More Headlines

AXDX Stock Analysis - Frequently Asked Questions

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings results on Thursday, March, 20th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.13. The medical research company earned $2.82 million during the quarter, compared to analyst estimates of $3 million.

Accelerate Diagnostics's stock reverse split on the morning of Wednesday, July 12th 2023.The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Netflix (NFLX).

Company Calendar

Last Earnings
3/20/2025
Today
8/30/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:AXDX
CIK
727207
Employees
220
Year Founded
2004

Profitability

EPS (Trailing Twelve Months)
($2.34)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$61.62 million
Net Margins
-471.83%
Pretax Margin
-444.14%
Return on Equity
N/A
Return on Assets
-191.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.50
Quick Ratio
1.34

Sales & Book Value

Annual Sales
$11.70 million
Price / Sales
0.07
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.37) per share
Price / Book
-0.02

Miscellaneous

Outstanding Shares
25,210,000
Free Float
14,125,000
Market Cap
$857.14 thousand
Optionable
No Data
Beta
0.22

Social Links

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NASDAQ:AXDX) was last updated on 8/30/2026 by MarketBeat.com Staff.
From Our Partners